Drug intelligence / Profile preview

PTB600

Development stage: Preclinical
Lead developer: NJ Bio
Modality: Small Molecules

Overview

**PTB600** is a discovery-stage, GSPT1-targeted molecular-glue degrader being developed by Protier Biotech for oncology. The small-molecule candidate is intended to promote degradation of G1 to S phase transition 1, a translation-termination factor, and is being investigated for solid tumors and hematologic malignancies. Protier Biotech lists PTB600 as a discovery candidate in its molecular-glue pipeline. ([protierbiotech.com](https://www.protierbiotech.com/en/pipeline))

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)GSPT1 (G1 to S phase transition 1)

Beyond the preview

Go deeper on PTB600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTB600.

Explore the full profile